936091-15-5

Basic information

• Product Name: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide
• Synonyms: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide;TG-46;N-(tert-Butyl)-3-((5-methyl-2-((4-(morpholinomethyl)phenyl)-amino)pyrimidin-4-yl)amino)benzene
• CAS NO: 936091-15-5
• Molecular Formula: C26H34N6O3S
• Molecular Weight: 511
• Mol File: 936091-15-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide(936091-15-5)
• EPA Substance Registry System: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide(936091-15-5)

Safety Data

• Hazardous Substances Data: 936091-15-5(Hazardous Substances Data)

Usage

General Description

N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide, also known as Pazopanib, is a medication used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking the action of a protein called vascular endothelial growth factor receptor (VEGFR), as well as other proteins that play a role in the growth and spread of cancer cells. This medication is typically taken orally and is available as a tablet. Common side effects may include diarrhea, nausea, vomiting, loss of appetite, and high blood pressure. However, it may also cause more serious side effects, such as liver problems, thyroid issues, and bleeding. Therefore, it is important for patients to be closely monitored by their healthcare provider while taking this medication.

Upstream product

• 936092-53-4 N-(tert-butyl)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)benzenesulfonamide 
• 51013-67-3 4-morpholinomethyl aniline 

Relevant articles and documents

BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.